Southwest Research Institute

Other

University of Texas System

Bernard Technologies, Inc.

Microactive Corp.

Hong Dixon

Stephen Thomas Wellinghoff

Joseph A McDonough

Barry K Norling

Henry Ralph Rawls

Larry Allen Cabell

Joel J Kampa

Sumner A Barenberg

Benjamin R Furman

Joseph A Mcdonough

William E Bauta

Peter N Gray

Michael D Lelah

Maria Lucy Kimmel

Kevin Fitzpatrick

Patricia Underwood

The present disclosure is directed at compositions of dimethyl trisulfide (DMTS) suitable for use for treatment of cyanide intoxication. The compositions show particularly useful stability such that the DMTS remains stable for therapeutic use at the identified time periods. The compositions are therefore particularly suitable for use in autoinjectors.

Compositions of dimethyl trisulfide (DMTS) as a cyanide antidote

The present disclosure relates to the preparation of polymorphic mixtures of Cepharanthine.2HCl. Mixtures of at least two polymorphic forms can be formed into a mobile liquid phase in organic/aqueous solvent mixtures along with enteric polymer that can be spray dried to produce solid particulate enteric formulations for medicinal drug-treatment applications.

Pharmaceutical salt forms of Cepharanthine and Tetrandrine

The present invention is directed at aqueous suspensions of oxime compounds, such as 2-pyridine aldoxime methyl chloride (2-PAM Cl) for autoinjectors. The suspensions are able to provide 600 mg of 2-PAM Cl in one relatively small dose of less than or equal to 1.0 mL, and are particularly useful for placement in relatively small size autoinjectors.

Aqueous suspensions of oximes for autoinjectors

Methods for preparing suspensions of active pharmaceutical ingredients for ensuing drug delivery. The suspension may include a mixture of a relatively low dosage API and a relatively high dosage API or a mixture of an API with a suitable excipient.

Dosage suspensions of active pharmaceutical ingredients

The present disclosure relates to a method of melt processing an active agent. The method may include encapsulating an active agent in a first polymer material exhibiting a first processing temperature Tand forming capsules including the active agent. The method may also include melt processing the capsules with a second polymer material exhibiting a second processing temperature T, wherein T&#x3e;T.

Processing of heat-sensitive active agents

The present disclosure relates to compositions and methods for producing nanoparticles to provide relatively more rapid delivery of such particles across the blood-brain barrier. The nanoparticles may be formed from bis-quaternary pyridinium-aldoxime salts that may also be of a specific polymorphic structure and which may be formed in either hydrophobic or hydrophilic type liquid media. In addition, the nanoparticle for transport across the blood-brain barrier may comprise a polymeric resin encapsulating a bis-quaternary pyridinium-2-aldoxime salt.

Nanoparticles for drug delivery to the central nervous system

The present disclosure is directed at a pharmaceutically active nanoparticle suspension that may be optically clear. Such suspensions may be formed by selective dissolution of a pharmaceutically active compound in a first solvent followed by introduction into a second solvent, such as an aqueous medium, without substantial use of surfactants and/or mechanical shear.

Pharmaceutically active nanosuspensions

The present invention relates to two phase systems of a bioactive ingredient in particle form that has limited or no solubility in a liquid medium, which provides stability to the bioactive ingredient that is similar to the bioactive ingredient when in the solid state. The bioactive ingredient may be capable of therapeutically treating for the presence of a cholinesterase inhibitor. The bio active ingredient comprises 1,1'-methlyenebis[4-[(hydroxyimino)methyl]-pyridinium]dimethanesulfonate.

Two phase bioactive formulations of bis-quaternary pyridinium oxime sulfonate salts

The present disclosure relates to non-aggregating nanoparticles and their associated methods of preparation. The nanoparticles may have a surface and a size range of 1 nm to 999 nm, along with a zeta potential of &#x2212;50 to 50 millivolts. A polycation and/or polyanion may be disposed on the nanoparticle surface. In addition, an active ingredient may be encapsulated within the nanoparticles or associated with the polycation or polyanion on the nanoparticle surface.

Modified calcium phosphate nanoparticle formation

A composition for energy-controlled generation and release of at least one gas, which includes an energy-activated catalyst capable of being activated by electromagnetic energy, and a solid or a liquid containing anions capable of being oxidized by the activated catalyst or reacted with species generated during activation of the catalyst to generate at least one gas. The composition, when exposed to electromagnetic energy, is capable of generating and releasing the gas after activation of the catalyst and oxidation or reaction of the anions.

Energy-activated compositions for controlled sustained release of a gas

Metal oxide nanoparticles having at least some surface acid sites functionalized with an adhesion promoter and at least some surface acid sites functionalized with a coupling agent. The nanoparticles are useful in forming composites comprising photopolymerizable matrix monomers, and are primarily suitable for dental and medical restoration. In a preferred embodiment, the metal oxide comprises zirconium, and the coupling agent is a zirconate.

Functionalized zirconium oxide particles

There are disclosed amphoteric nano-sized metal oxide particles functionalized with silyl esters of a phosphonate and composites thereof with an acrylate-based monomer, including liquid crystal monomers photopolymerizable at ambient temperature. Also disclosed are the method making such functionalized particular by reacting a metal oxide with a silyl ester of a phosphonate in the presence of a non-aqueous solvent and in an inert atmosphere and the method of making the composites wherein the functionalized particles are admixed with an acrylate-based matrix monomer, including liquid crystal monomers photopolymerizable at ambient temperature. Further disclosed is the method of dental repair wherein the composites are applied to a tooth and photopolymerized.

Composites made using functionalized nanoparticles

Functionalized nanoparticles

Methods of dental repair using functionalized nanoparticles

Metal oxide and metal oxide-silica nanoparticles are disclosed wherein the surfaces thereof are complexed with a polymerizable, biocompatible, heterocyclic base. Polymerizable compositions are prepared by loading such nanoparticles into acrylate based monomer matrices, which compositions can then be photocured into X-ray opaque, transparent or translucent solids. Methods are disclosed for forming such complexed nanoparticles and compositions and for using such compositions as medical or dental restoratives.

Growing community of inventors

Helotes, TX, United States of America

Hong Dixon